Does sildenafil reduce the risk of fetal distress in labour?
Investigating if Sildenafil Citrate (50mg PO 8hrly) administration in labour reduces the rates of emergency operative delivery for fetal distress and improves fetal and uteroplacental blood flow on Dopper ultrasound in term (37-42 weeks), singleton, appropriately grown pregnancies
Mater Health Service
640 participants
Sep 29, 2015
Interventional
Conditions
Summary
Labour is perhaps the most hazardous time in pregnancy for the fetus. Uterine contractions can contribute to more than a halving of blood flow to the uterus and placenta and this in turn may lead to fetal distress. In most pregnancies, the placental blood supply and function is adequate but it may not be sufficient to tolerate the extra demands of labour. Up to 63% of babies who become distressed and suffer oxygen deprivation in labour have no prior risk factors. Furthermore, events in labour account for as many as 20% of cases of cerebral palsy in term infants. Recent research demonstrates that the changes in blood flow to the fetus can be detected by ultrasound and that these changes are highly predictive of identifying fetuses at risk of becoming distressed in labour, as well as reliably excluding those that were not at risk. With this in mind, investigating ways to preserve and promote the blood supply and in turn, the oxygenation to the fetus has the potential to significantly change intrapartum care. Sildenafil is a vasodilator (opens blood vessels) and based on previous research may play a role in enhancing blood flow to the fetus. This clinical trial will investigate if having sildenafil in labour improves the blood flow to the fetus and reduces the need for emergency operative delivery (either caesarean section or operative vaginal birth) for fetal distress.
Eligibility
Inclusion Criteria5
- Aged between 18-50 who are able to give informed consent
- Singleton pregnancy at 37-42 weeks gestation
- Appropriately grown fetus without any structural, chromosomal or genetic abnormality.
- Admitted in spontaneous labour (cervical dilatation <4cm) or prior to induction of labour
- Planning a vaginal delivery
Exclusion Criteria4
- Women <18 years old
- Those unable to give informed consent
- Women with pre-existing heart disorders, stroke, hypotension or hypertension, retinitis pigmentosa, kidney or liver abnormalities, sickle cell anaemia, stomach ulcers or any other bleeding disorder.
- Women on any anti-hypertensive medication.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Participants will be randomised to either placebo orally 8 hourly (maximum three doses in 24 hours) or sildenafil citrate 50mg orally 8 hourly (maximum 150mg in 24 hours). Only women at term (37-42 weeks of pregnancy) are eligible. Participants will be randomised when delivery is anticipated within 72 hours and dosing regimen commenced when transferred to birth suite for management of labour. Doses will be administered intrapartum in labour ward by medical and midwifery staff under supervision and unused drug tablets will be returned and disposed of in adherence with hospital policy.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12615000319572